Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Gait Disorders and Attention Deficit in Parkinson's Disease
NCT01108029Phase 4Completed
- Sponsor
- CHU de Lille
- Start
- Oct 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) and gait disorder comparing memantine with placebo (2 arms). Primary endpoint: Stride length by gait analysis with an optoelectronic system (VICON®) at 3 months. Started Oct 2009; status: completed.
02
Drugs
memantine
03
Conditions
Parkinson's disease (PD)gait disorder
Beyond the preview
Go deeper on NCT01108029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01108029.